Sam Ngan is a radiation oncologist with special interest in GI cancers and sarcoma. He was previously a consultant surgeon and a lecturer in surgery at the University of Hong Kong. He has been a consultant of the GI Unit at Peter Mac since 1991, and the Head of the Unit since 1999. He attends Box Hill Hospital as an honorary consultant. His experience in clinical research in rectal cancer includes study conception and design, recruitment, quality assurance, analysis and interpretation of data. He has been a principal investigator of six multi-centre rectal trials. Research awards include TROG Cancer Research Trial Excellence Award in 2007 and TROGIE for Trial Excellence in 2016.
Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, Ackland SP, Schache D, McClure B, McLachlan SA, McKendrick J, Leong T,J Hartopeanu, Zalcberg J, Mackay J. Randomized trial of short course radiotherapy versus long course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. J Clin Oncol. 2012 Nov 1;30(31):3827-33.
Tan J, Heriot A, Mackay J, Van Dyke S, Fox C, Bressel M, Hui A, Lynch C, Leong T, Ngan S. A Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer. J Med Imaging Radiat Oncol. 2013 Oct;57(5):617-25.
McLachlan SA, Fisher RJ, Zalcberg J, Solomon M, Burmeister B, Goldstein D, Leong T, Ackland SP, McKendrick J, McClure B, Mackay J, Ngan SY. The impact on health-related quality of life in the first 12 months: A randomized comparison of pre-operative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). Eur J Cancer. 2016 Mar;55:15-26.
Ansari N, Solomon MJ, Fisher RJ, Mackay J, Burmeister B, Ackland S, Heriot A, Joseph D, McLachlan SA, McClure B, Ngan SY. Acute adverse events and postoperative complications in a randomised trial of preoperative short-course radiotherapy versus long-course chemoradiotherapy for T3 adenocarcinoma of the rectum: Trans-Tasman Radiation Oncology Group trial (TROG 01.04). Ann Surg. 2017 May;265(5):882-888.
Bird T, Michael M, Bressel M, Chu J, Chander S, Cooray P, McKendrick J, Jefford M, Heriot A, Steel M, Leong T, Ngan S. FOLFOX and intensified split-course chemoradiation as initial treatment for rectal cancer with synchronous metastases. Acta Oncol. 2017 Mar 16:1-7.
Czito BG, Deming DA, Jameson GS, Mulcahy MF, Vaghefi H, Dudley MW, Holen KD, DeLuca A, Mittapalli RK, Munasinghe W, He L, Zalcberg JR, Ngan SY, Komarnitsky P, Michael M. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):418-426.
Penniment MG, De Ieso PB, Harvey JA, Stephens S, Au HJ, O'Callaghan CJ, Kneebone A, Ngan SY, Ward IG, Roy R, Smith JG, Nijjar T, Biagi JJ, Mulroy LA, Wong R; TROG 03.01/CCTG ES.2 group. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). Lancet Gastroenterol Hepatol. 2017 Dec 13. pii: S2468-1253(17)30363-1.